98 F.4th 483
4th Cir.2024Background
- The Medicaid Drug Rebate Program requires manufacturers to pay rebates to Medicaid when drug prices rise faster than inflation; initially, a statutory loophole allowed manufacturers to avoid extra rebates by making new versions (“line extensions”) of drugs.
- In 2010, Congress added a provision to close this loophole by subjecting certain “line extension” drugs to higher rebates, not just based on their own price increases but also those of their originating drugs.
- In 2020, CMS promulgated a regulation clarifying what constitutes a “line extension” drug and how the oral-solid-dosage-form requirement applies.
- Vanda Pharmaceuticals challenged the regulation as improperly broad, asserting it exceeded the statutory definition and imposed higher rebates unfairly.
- The district court granted summary judgment for CMS, upholding the regulation as consistent with the Medicaid statute and proper under the Administrative Procedure Act (APA).
- Vanda appealed, and the Fourth Circuit reviewed the case de novo.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Definition of “Line Extension” and “New Formulation” | Vanda argued the regulation’s definitions were too broad, encompassing changes beyond what Congress intended. | CMS argued its definitions tracked the statute and filled statutory gaps as Congress intended, allowing broader agency discretion. | Court upheld CMS, finding the definitions fell within statutory bounds and reflected congressional intent to be inclusive. |
| Oral Solid Dosage Form Requirement | Vanda contended both the original and line-extension drugs had to be oral solid forms for the provision to apply. | CMS read the statute as requiring only the original drug to be in oral solid form, not the line extension. | Court agreed with CMS, finding the statute’s phrasing and grammar supported the agency’s interpretation. |
| APA Arbitrary and Capricious Review | Vanda claimed the regulation was arbitrary and capricious for ignoring practical inconsistencies, industry reliance, and innovation chilling effects. | CMS argued it reasonably explained its policy change, addressed comments, and that any "inconsistency" resulted from statute, not regulation. | Court held CMS’s rulemaking was reasonable and satisfied APA procedural requirements. |
| Scope of FDA New Drug Applications | Vanda argued drugs requiring new FDA applications should not be subject to "line extension" rebates, claiming these are fundamentally new drugs. | CMS countered statutory language and congressional intent do not support such a limitation; FDA approval process is irrelevant to rebate calculation. | Court rejected Vanda’s restriction, finding no statutory basis to limit line extensions based on FDA application type. |
Key Cases Cited
- Chevron U.S.A., Inc. v. Natural Res. Def. Council, 467 U.S. 837 (establishes Chevron deference for agency statutory interpretation)
- Skidmore v. Swift & Co., 323 U.S. 134 (establishes Skidmore deference based on agency persuasiveness)
- Barnhart v. Thomas, 540 U.S. 20 (applies last antecedent rule for statutory interpretation)
- Jama v. Immigration & Customs Enf’t, 543 U.S. 335 (cautions against inferring statutory requirements not explicitly stated)
- FCC v. Prometheus Radio Project, 592 U.S. 414 (sets standard for reviewing agency action under APA as reasonable and explained)